Anti-Human 4-1BB & HER2 Bispecific Reference Antibody (Cinrebafusp Alfa, RUO)
- Catalog number: BS12489
- Availability: In Stock
$482.00
- Ex Tax: $482.00
Description: Cinrebafusp alfa (BS12489) is a research-grade recombinant antibody targeting CD137. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: Bispecific,Tumornecrosisfactorreceptorsuperfamilymember9,CD137,4-1BBligandreceptor,CDw137,TNFRSF9,T-cellantigenILA,T-cellantigen4-1BBhomolog,ILA,p185erbB2,HER2,NGL,Tyrosinekinase-typecellsurfacereceptorHER2,NEU,MLN19,Proto-oncogeneNeu,MLN19,ERBB2,Proto-oncogenec-ErbB-2,CD340,Receptortyrosine-proteinkinaseerbB-2,Metastaticlymphnodegene19protein
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: Bispecific,Tumornecrosisfactorreceptorsuperfamilymember9,CD137,4-1BBligandreceptor,CDw137,TNFRSF9,T-cellantigenILA,T-cellantigen4-1BBhomolog,ILA,p185erbB2,HER2,NGL,Tyrosinekinase-typecellsurfacereceptorHER2,NEU,MLN19,Proto-oncogeneNeu,MLN19,ERBB2,Proto-oncogenec-ErbB-2,CD340,Receptortyrosine-proteinkinaseerbB-2,Metastaticlymphnodegene19protein
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
Note: For research use only. Not suitable for clinical or therapeutic use.
